Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll HuR modulates gemcitabine efficacy: new perspectives in pancreatic cancer treatment Marechal R; Van Laethem JLExpert Rev Anticancer Ther 2009[Oct]; 9 (10): 1439-41EVALUATION OF: Costantino CL, Witkiewicz AK, Kuwano Y et al. The role of HuR in gemcitabine efficacy in pancreatic cancer: HuR up-regulates the expression of the gemcitabine metabolizing enzyme deoxycytidine kinase. Cancer Res. 69, 4567-4572 (2009). Gemcitabine has been the standard of care for pancreatic cancer for a decade but is only effective in some patients. As a prodrug, gemcitabine is activated by different protein kinases. The deoxycytidine kinase (dCK) is the first step of intracellular activation. We review the study by Costantino and colleagues, evaluating the consequence of modulating Hu antigen R (HuR), a stress response protein, on dCK expression and the correlation between HuR expression levels and pancreatic cancer outcome. This study demonstrates that dCK protein concentration levels were regulated by HuR and that a high cytoplasmic HuR level was associated with a sevenfold decreased risk of mortality after resection of pancreatic adenocarcinoma and gemcitabine therapy.|Antigens, Surface/genetics[MESH]|Antimetabolites, Antineoplastic/metabolism/pharmacology/*therapeutic use[MESH]|Carcinoma, Pancreatic Ductal/drug therapy/genetics[MESH]|Cytoplasm/metabolism[MESH]|Deoxycytidine Kinase/genetics[MESH]|Deoxycytidine/*analogs & derivatives/metabolism/pharmacology/therapeutic use[MESH]|ELAV Proteins[MESH]|ELAV-Like Protein 1[MESH]|Gemcitabine[MESH]|Gene Expression Regulation, Neoplastic[MESH]|Humans[MESH]|Pancreatic Neoplasms/*drug therapy/genetics/mortality[MESH]|Prodrugs[MESH]|RNA-Binding Proteins/genetics[MESH]|Treatment Outcome[MESH] |